NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,006 DKK | +0.30% |
|
+1.79% | +44.05% |
| 12:42pm | India plans incentives for diabetes, obesity drug makers in 2026, government official says | RE |
| 09:22am | NOVO NORDISK : UBS gives a Neutral rating | ZD |
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,003
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +44.05% | 64TCr | |
| +55.78% | 82TCr | |
| -6.90% | 35TCr | |
| +16.53% | 33TCr | |
| +10.13% | 30TCr | |
| +16.57% | 24TCr | |
| +2.04% | 23TCr | |
| +13.31% | 22TCr | |
| +8.60% | 17TCr | |
| -2.95% | 16TCr |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk's Wegovy Weight-Loss Drug Gets Approval in China
